RecruitingNot ApplicableNCT04932525

Gustave Roussy Cancer Profiling


Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Enrollment

20,000 participants

Start Date

May 10, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

The objective of STING study is to perform high throughput molecular analysis (next generation sequencing +/- immunological profiling) to estimate the proportion of patients with cancer presenting at least one targetable genomic alteration.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Age ≥ 18 years
  • Histology: solid malignant tumor or hematological malignancy.
  • Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code)
  • Voluntary signed and dated written informed consent prior to any study specific procedure.

Exclusion Criteria4

  • Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in a clinical trial or which would jeopardize compliance with the protocol
  • Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
  • Pregnant or breast-feeding women
  • Minors (Age < 18 years)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBiopsy

Blood and tumor samples for Genetic Profiling research


Locations(4)

Gustave Roussy Cancer Campus Grand Paris

Villejuif, Val de Marne, France

Hôpital Marie-Lannelongue

Le Plessis-Robinson, France

Hôpital Saint-Joseph

Paris, France

Hôpital Foch

Suresnes, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04932525


Related Trials